ENMD-2076 tartrate, reported at 200 mg/kg orally once daily, inhibited day-30 tumor growth in two of three TP53-mutated TNBC PDX models. CU_TNBC_004 did not show significant inhibition, despite pharmacodynamic marker changes. Significant tumor regression was not observed. The tested salt and reported doses are not assumed equivalent to the catalog free base. [2]
Initially responsive PDX tumors regrew during continued ENMD-2076 tartrate treatment. In selected tumors, Ki67 recovered while CD34 staining remained reduced, indicating that the vascular-marker response did not ensure sustained growth control. [2]
Tartrate ENMD-2076 initial response in three TNBC PDX models
Animal study · Three TP53-mutated human TNBC PDX models in female athymic nude mice [2]
At day 30, two PDX models showed significant growth inhibition and one did not. pAurA reduction occurred in both a sensitive and a resistant model; target-associated marker changes did not guarantee tumor response.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Once daily, continuous dosing
- Treatment course
- 30 days
- Vehicle
- Drug prepared as 40 mg/mL stock in water; control identified as vehicle, composition not separately specified.
- CU_TNBC_002 tartrate treatment versus vehicle
- Model: CU_TNBC_002 TNBC PDX
- Reported limits: No conversion to catalog free base; exact animal counts per model beyond at least 10 tumors/group are not provided in the adopted text.
- CU_TNBC_005 tartrate treatment versus vehicle
- Model: CU_TNBC_005 TNBC PDX
- Reported limits: No conversion to catalog free base; exact animal counts per model beyond at least 10 tumors/group are not provided in the adopted text.
- CU_TNBC_004 tartrate treatment versus vehicle
- Model: CU_TNBC_004 TNBC PDX
- Reported limits: No conversion to catalog free base; exact animal counts per model beyond at least 10 tumors/group are not provided in the adopted text.
Methods and source locations
Compound reported in the paper: ENMD-2076; Compound label in the paper: ENMD-2076 tartrate salt, supplied by CASI
Related-form animal evidence only: tested material was tartrate. Reported mg/kg doses are reproduced as written; mass basis was not clarified as salt versus free-base equivalent.
Figure 1A-B and caption; Methods: Drugs, In Vivo TNBC PDX Studies, Immunofluorescence, Statistical Analysis; Results: Antitumor Activity and Pharmacodynamic Effects; Discussion
Day-30 tumor growth inhibition against vehicle in the three models: TGI = 1 − (average treated tumor volume / average vehicle tumor volume); unpaired t-test with Welch correction reported. — Figure 1A and caption; Results: Antitumor Activity; Methods: In Vivo TNBC PDX Studies and Statistical Analysis
pAurA and pHH3 in CU_TNBC_005 and CU_TNBC_004 at days 4 and 30: Immunofluorescence images with DAPI; qualitative observation from original Results and Figure 1B. — Figure 1B and caption; Results: Pharmacodynamic Effects; Methods: Immunofluorescence
CU_TNBC_002 tartrate treatment versus vehicle · Methods: Drugs and In Vivo TNBC PDX Studies; Figure 1A and caption
CU_TNBC_005 tartrate treatment versus vehicle · Methods: Drugs and In Vivo TNBC PDX Studies; Figure 1A and caption
CU_TNBC_004 tartrate treatment versus vehicle · Methods: Drugs and In Vivo TNBC PDX Studies; Figure 1A and caption
Continued tartrate dosing and regrowth in initially sensitive PDX tumors
Animal study · Longitudinal continuation in initially sensitive CU_TNBC_002 and CU_TNBC_005 PDX tumors; selected tumor tissues for correlative analysis [2]
Tumors regrew during continued treatment. Ki67 recovered toward vehicle levels while CD34 staining remained reduced in selected tissues. These associations show that persistent vascular-marker changes did not ensure durable tumor control.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Once daily, continuous dosing
- Treatment course
- Continued beyond day 30 until regrowth; selected individual tumors have differing endpoint times.
- Vehicle
- Drug stock prepared in water; vehicle composition not separately specified.
- CU_TNBC_002 continued tartrate treatment
- Model: Initially sensitive CU_TNBC_002 TNBC PDX; selected individual tumors
- Reported limits: No extension cohort size or uniform course inferred from selected individual curves.
- CU_TNBC_005 continued tartrate treatment
- Model: Initially sensitive CU_TNBC_005 TNBC PDX; selected individual tumors
- Reported limits: No extension cohort size or uniform course inferred from selected individual curves.
Methods and source locations
Compound reported in the paper: ENMD-2076; Compound label in the paper: ENMD-2076 tartrate salt, supplied by CASI
Related-form animal evidence only: tested material was tartrate. Reported mg/kg doses are reproduced as written; mass basis was not clarified as salt versus free-base equivalent.
Figure 2A-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Drugs, In Vivo TNBC PDX Studies and Immunohistochemistry
Regrowth during continued ENMD-2076 dosing in initially responsive tumors: Individual tumor curves and selected-tumor comparison; this criterion is relative to day 30, not pretreatment baseline. — Figure 2A-B and caption; Results: ENMD-2076 Treatment to Acquired Resistance
Ki67 and CD34 in selected initial-response and later-regrowth tissues: Representative IHC; correlative samples selected based on mean tumor volume to minimize necrotic tissue. At least three samples from at least two animals assessed per time point (general IHC method). — Figure 2C-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Immunohistochemistry
CU_TNBC_002 continued tartrate treatment · Figure 2A-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Drugs and In Vivo TNBC PDX Studies
CU_TNBC_005 continued tartrate treatment · Figure 2A-D and caption; Results: ENMD-2076 Treatment to Acquired Resistance; Methods: Drugs and In Vivo TNBC PDX Studies